Success Metrics

Clinical Success Rate
84.7%

Based on 105 completed trials

Completion Rate
85%(105/124)
Active Trials
16(9%)
Results Posted
46%(48 trials)
Terminated
19(11%)

Phase Distribution

Ph not_applicable
30
17%
Ph phase_2
59
34%
Ph early_phase_1
7
4%
Ph phase_1
32
18%
Ph phase_3
26
15%
Ph phase_4
21
12%

Phase Distribution

39

Early Stage

59

Mid Stage

47

Late Stage

Phase Distribution175 total trials
Early Phase 1First-in-human
7(4.0%)
Phase 1Safety & dosage
32(18.3%)
Phase 2Efficacy & side effects
59(33.7%)
Phase 3Large-scale testing
26(14.9%)
Phase 4Post-market surveillance
21(12.0%)
N/ANon-phased studies
30(17.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

105 of 128 finished

Non-Completion Rate

18.0%

23 ended early

Currently Active

16

trials recruiting

Total Trials

176

all time

Status Distribution
Active(20)
Completed(105)
Terminated(23)
Other(28)

Detailed Status

Completed105
unknown26
Terminated19
Recruiting12
Withdrawn4
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
176
Active
16
Success Rate
84.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 17 (4.0%)
Phase 132 (18.3%)
Phase 259 (33.7%)
Phase 326 (14.9%)
Phase 421 (12.0%)
N/A30 (17.1%)

Trials by Status

suspended21%
completed10560%
withdrawn42%
not_yet_recruiting32%
recruiting127%
active_not_recruiting42%
terminated1911%
enrolling_by_invitation11%
unknown2615%

Recent Activity

Clinical Trials (176)

Showing 20 of 176 trialsScroll for more
NCT05142735Not Applicable

Effects of NAC on Symptoms of CHR Patients

Recruiting
NCT07464886Phase 3

Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth

Recruiting
NCT05123365Phase 1

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Recruiting
NCT04520139Phase 1

Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT

Not Yet Recruiting
NCT06260566Phase 1

Tolerability of Enteral NAC in Infants

Not Yet Recruiting
NCT05537220Phase 3

Oral N-acetylcysteine for Retinitis Pigmentosa

Active Not Recruiting
NCT02583672Phase 2

Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

Completed
NCT05241262Phase 1

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Recruiting
NCT04278898Phase 2

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Single-dose

Recruiting
NCT05494398Phase 2

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Enrolling By Invitation
NCT05294744Not Applicable

Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

Recruiting
NCT04374461Phase 2

A Study of N-acetylcysteine in Patients With COVID-19 Infection

Active Not Recruiting
NCT05610072Early Phase 1

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Recruiting
NCT06377410Not Applicable

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients

Recruiting
NCT01467466Phase 3

Prevention of Serious Adverse Events Following Angiography

Completed
NCT05081479Phase 1

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Active Not Recruiting
NCT04155632Phase 2

Neurocircuit Strategy to Decrease Cocaine Cue Reactivity

Completed
NCT06236165Phase 2

Clinical Study Evaluating Efficacy, Safety and Molecular Mechanism of N-acetylcysteine Supplementation in Patients With Hepatic and Post Hepatic Jaundice

Completed
NCT04740580Early Phase 1

Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease

Recruiting
NCT02719392Phase 4

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

Suspended

Drug Details

Intervention Type
DRUG
Total Trials
176